\-\ Texto\\:\\ \ \(0\)\
\-\ the\\ patient\\ appeared\\ uncomfortable\\ and\\ in\\ significant\\ pain\\.\\ \\ \ \(0\)\
\-\ laboratory\\ values\\ were\\ significant\\ for\\ a\\ urine\\ analysis\\ which\\ demonstrated\\ a\\ large\\ amount\\ of\\ blood\\ with\\ over\\ 100\\ rbcs\\.\\ \\ the\\ ua\\ also\\ showed\\ greater\\ than\\ 300\\ protein\\.\\ \\ the\\ urine\\ culture\\ was\\ negative\\ for\\ growth\\.\\ \\ the\\ patient\\ was\\ afebrile\\ and\\ without\\ an\\ elevated\\ white\\ blood\\ cell\\ count\\.\ \(0\)\
\-\ patient\\ is\\ being\\ treated\\ nonsurgically\\.\\ \\ he\\ is\\ receiving\\ chemotherapy\\ and\\ will\\ be\\ reevaluated\\ with\\ follow\\ up\\ imaging\\.\ \(0\)\
\-\ limited\\ evaluation\\ of\\ the\\ unopacified\\ abdominal\\ viscera\\ demonstrates\\ a\\ right\\ peripelvic\\ cyst\\.\\ \\ no\\ hydronephrosis\\ is\\ appreciated\\.\\ \\ the\\ right\\ ureter\\ is\\ mildly\\ dilated\\,\\ and\\ there\\ is\\ mild\\ perinephric\\ fat\\ stranding\\,\\ right\\ greater\\ than\\ left\\.\\ \\ however\\,\\ no\\ pathologic\\ calcifications\\ are\\ seen\\ within\\ the\\ renal\\ collecting\\ systems\\ or\\ along\\ the\\ course\\ of\\ the\\ bilateral\\ ureters\\.\ \(0\)\
\-\ the\\ posterior\\ bladder\\ wall\\ has\\ a\\ thickened\\ irregular\\ appearance\\.\\ \\ hu\\ measurement\\ was\\ 50\\ consistent\\ with\\ soft\\ tissue\\.\ \(0\)\
\-\ this\\ contour\\ irregularity\\ was\\ further\\ evaluated\\ on\\ a\\ contrast\\ study\\.\\ \\ this\\ showed\\ an\\ extensively\\ thickened\\ posterior\\ bladder\\ wall\\ which\\ did\\ not\\ demonstrate\\ enhancement\\.\\ \\ \ \(0\)\
\-\ the\\ ureterovesicle\\ junction\\ is\\ outlined\\ by\\ contrast\\ on\\ the\\ left\\.\\ \\ contrast\\ was\\ not\\ seen\\ to\\ enter\\ through\\ the\\ right\\ ureterovesicle\\ junction\\.\ \(0\)\
\-\ primary\\ lymphoma\\ of\\ the\\ bladder\ \(0\)\
\-\ based\\ on\\ the\\ ct\\ findings\\,\\ transitional\\ cell\\ carcinoma\\ would\\ have\\ to\\ be\\ excluded\\.\\ \\ invasion\\ from\\ prostate\\ cancer\\ would\\ also\\ be\\ a\\ consideration\\.\\ \\ in\\ general\\,\\ focal\\ bladder\\ wall\\ thickening\\ can\\ be\\ seen\\ in\\ acute\\ or\\ chronic\\ inflammation\\ such\\ as\\ cystitis\\,\\ focal\\ muscle\\ hypertrophy\\,\\ squamous\\ cell\\ carcinoma\\,\\ \\ leiomyosarcoma\\,\\ neurofibroma\\,\\ or\\ hemangioma\\.\ \(0\)\
\-\ 39\\-year\\ old\\ male\\ presented\\ to\\ the\\ emergency\\ room\\ with\\ the\\ complaint\\ of\\ gross\\ hematuria\\ and\\ left\\ flank\\ pain\\.\\ \\ a\\ noncontrast\\ ct\\ of\\ the\\ abdomen\\ and\\ pelvis\\ was\\ requested\\ to\\ rule\\ out\\ stones\\.\ \(0\)\
\-\ primary\\ lymphoma\\ of\\ the\\ bladder\\ is\\ rare\\,\\ and\\ less\\ than\\ 100\\ cases\\ have\\ been\\ discussed\\ in\\ the\\ literature\\.\\ \\ secondary\\ involvement\\ of\\ the\\ bladder\\ by\\ lymphoma\\ from\\ other\\ sites\\ occurs\\ in\\ approximately\\ 13\\%\\ of\\ patients\\.\\ \\ \ \(0\)\
\-\ primary\\ lymphoma\\ of\\ the\\ bladder\\ is\\ thought\\ to\\ typically\\ affect\\ elderly\\ females\\ with\\ a\\ history\\ of\\ chronic\\ cystitis\\.\\ \\ the\\ female\\ to\\ male\\ ration\\ is\\ \\>6\\ to\\ 1\\ with\\ a\\ median\\ age\\ of\\ presentation\\ of\\ 65\\ years\\.\\ \\ this\\ case\\ is\\ certainly\\ unique\\ given\\ that\\ the\\ patient\\ is\\ a\\ young\\ male\\ without\\ a\\ history\\ of\\ chronic\\ bladder\\ infections\\.\\ \\ in\\ addition\\,\\ the\\ lymphoma\\ caused\\ obstruction\\ of\\ the\\ ureterovesicle\\ junction\\ on\\ the\\ right\\.\ \(0\)\
\-\ treatment\\ options\\ include\\ observation\\,\\ chemotherapy\\ and\\ radiation\\ treatment\\.\\ \\ radical\\ surgery\\ has\\ also\\ been\\ performed\\.\\ \\ however\\,\\ according\\ to\\ the\\ literature\\ this\\ is\\ felt\\ to\\ be\\ unnecessary\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ bladder\\:\\ 0\\.062353454260656714\ \(0\)\
\-\ ureterovesicle\\:\\ 0\\.05943046128516741\ \(0\)\
\-\ lymphoma\\:\\ 0\\.027440434094263885\ \(0\)\
\-\ cystitis\\:\\ 0\\.026386873909213748\ \(0\)\
\-\ junction\\:\\ 0\\.024128605355976735\ \(0\)\
\-\ literature\\:\\ 0\\.02065622794961974\ \(0\)\
\-\ 39\\-year\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ 100\\:\\ 0\\.019396443836567343\ \(0\)\
\-\ urine\\:\\ 0\\.01853559794039261\ \(0\)\
\-\ nonsurgically\\:\\ 0\\.018252519648104613\ \(0\)\
\-\ peripelvic\\:\\ 0\\.018252519648104613\ \(0\)\
\-\ ration\\:\\ 0\\.018252519648104613\ \(0\)\
\-\ reevaluated\\:\\ 0\\.01734136210179413\ \(0\)\
\-\ thickened\\:\\ 0\\.017222075515767023\ \(0\)\
\-\ primary\\:\\ 0\\.017065511884690087\ \(0\)\
\-\ unopacified\\:\\ 0\\.01669488553448676\ \(0\)\
\-\ wall\\:\\ 0\\.016686465979137616\ \(0\)\
\-\ chronic\\:\\ 0\\.016226896401620224\ \(0\)\
\-\ cell\\:\\ 0\\.015561173336504402\ \(0\)\
\-\ uncomfortable\\:\\ 0\\.015437321966092552\ \(0\)\
\-\ is\\:\\ 0\\.015162897394644288\ \(0\)\
\-\ extensively\\:\\ 0\\.015137251420868905\ \(0\)\
\-\ than\\:\\ 0\\.01509471138147151\ \(0\)\
\-\ be\\:\\ 0\\.014806255318471113\ \(0\)\
\-\ greater\\:\\ 0\\.01442569149514832\ \(0\)\
\-\ viscera\\:\\ 0\\.014421625058804783\ \(0\)\
\-\ 300\\:\\ 0\\.013879687852474697\ \(0\)\
\-\ unnecessary\\:\\ 0\\.013879687852474697\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.013766048472543216\ \(0\)\
\-\ rbcs\\:\\ 0\\.013724647691829862\ \(0\)\
\-\ outlined\\:\\ 0\\.013724647691829862\ \(0\)\
\-\ would\\:\\ 0\\.013667266869312765\ \(0\)\
\-\ enter\\:\\ 0\\.013443382202045578\ \(0\)\
\-\ certainly\\:\\ 0\\.013443382202045578\ \(0\)\
\-\ was\\:\\ 0\\.013325090187150834\ \(0\)\
\-\ contrast\\:\\ 0\\.012895116989716217\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.012668459760940567\ \(0\)\
\-\ showed\\:\\ 0\\.012592374237859312\ \(0\)\
\-\ measurement\\:\\ 0\\.012576724941793928\ \(0\)\
\-\ hu\\:\\ 0\\.01240377878193746\ \(0\)\
\-\ unique\\:\\ 0\\.01224319684040455\ \(0\)\
\-\ perinephric\\:\\ 0\\.012167013578212007\ \(0\)\
\-\ radical\\:\\ 0\\.012021983193633195\ \(0\)\
\-\ ureters\\:\\ 0\\.011820607556128281\ \(0\)\
\-\ transitional\\:\\ 0\\.011757302214630087\ \(0\)\
\-\ seen\\:\\ 0\\.011384006393714766\ \(0\)\
\-\ also\\:\\ 0\\.011356986024742593\ \(0\)\
\-\ elderly\\:\\ 0\\.011306356831569072\ \(0\)\
\-\ requested\\:\\ 0\\.011206465230286301\ \(0\)\
\-\ receiving\\:\\ 0\\.011110825647322714\ \(0\)\
\-\ median\\:\\ 0\\.011110825647322714\ \(0\)\
\-\ affect\\:\\ 0\\.011064490170462633\ \(0\)\
\-\ focal\\:\\ 0\\.010968510580397313\ \(0\)\
\-\ carcinoma\\:\\ 0\\.010885068179846592\ \(0\)\
\-\ consideration\\:\\ 0\\.010724645294678536\ \(0\)\
\-\ however\\:\\ 0\\.010693789013919418\ \(0\)\
\-\ females\\:\\ 0\\.010685562726786696\ \(0\)\
\-\ according\\:\\ 0\\.010685562726786696\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.010647148269799504\ \(0\)\
\-\ discussed\\:\\ 0\\.010499738646235879\ \(0\)\
\-\ blood\\:\\ 0\\.010482746393300223\ \(0\)\
\-\ appeared\\:\\ 0\\.01046434908001534\ \(0\)\
\-\ sites\\:\\ 0\\.01046434908001534\ \(0\)\
\-\ been\\:\\ 0\\.010448516357141535\ \(0\)\
\-\ male\\:\\ 0\\.010417115985758247\ \(0\)\
\-\ excluded\\:\\ 0\\.01039519928525859\ \(0\)\
\-\ ureter\\:\\ 0\\.010361406302416928\ \(0\)\
\-\ significant\\:\\ 0\\.010327402926086398\ \(0\)\
\-\ irregularity\\:\\ 0\\.010262973442510426\ \(0\)\
\-\ noncontrast\\:\\ 0\\.010262973442510426\ \(0\)\
\-\ culture\\:\\ 0\\.010231097858258839\ \(0\)\
\-\ ua\\:\\ 0\\.010199668101012232\ \(0\)\
\-\ systems\\:\\ 0\\.010199668101012232\ \(0\)\
\-\ prostate\\:\\ 0\\.010199668101012232\ \(0\)\
\-\ right\\:\\ 0\\.010130693360791199\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.009880174867797529\ \(0\)\
\-\ stones\\:\\ 0\\.009880174867797529\ \(0\)\
\-\ protein\\:\\ 0\\.009853262078928504\ \(0\)\
\-\ observation\\:\\ 0\\.009853262078928504\ \(0\)\
\-\ a\\:\\ 0\\.009803590606751941\ \(0\)\
\-\ collecting\\:\\ 0\\.009800384556658406\ \(0\)\
\-\ analysis\\:\\ 0\\.009774405180476214\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.009673390825729548\ \(0\)\
\-\ values\\:\\ 0\\.0096005025656101\ \(0\)\
\-\ squamous\\:\\ 0\\.009395032439858118\ \(0\)\
\-\ 65\\:\\ 0\\.0093733202805059\ \(0\)\
\-\ appreciated\\:\\ 0\\.009351815896199945\ \(0\)\
\-\ options\\:\\ 0\\.009330515347987487\ \(0\)\
\-\ contour\\:\\ 0\\.009309414807875487\ \(0\)\
\-\ stranding\\:\\ 0\\.00928851055470175\ \(0\)\
\-\ invasion\\:\\ 0\\.009247276535222657\ \(0\)\
\-\ gross\\:\\ 0\\.009147384933939883\ \(0\)\
\-\ infections\\:\\ 0\\.00912792861316884\ \(0\)\
\-\ hematuria\\:\\ 0\\.009108639301502791\ \(0\)\
\-\ without\\:\\ 0\\.0090427558038569\ \(0\)\
\-\ flank\\:\\ 0\\.009033096355887095\ \(0\)\
\-\ felt\\:\\ 0\\.009033096355887095\ \(0\)\
\-\ afebrile\\:\\ 0\\.00887187409777734\ \(0\)\
\-\ complaint\\:\\ 0\\.00887187409777734\ \(0\)\
\-\ posterior\\:\\ 0\\.00885230808405595\ \(0\)\
\-\ thought\\:\\ 0\\.008837565171640737\ \(0\)\
\-\ evaluated\\:\\ 0\\.008803772188799072\ \(0\)\
\-\ the\\:\\ 0\\.008698831397082073\ \(0\)\
\-\ 13\\:\\ 0\\.008673463744640984\ \(0\)\
\-\ this\\:\\ 0\\.008639435625295578\ \(0\)\
\-\ to\\:\\ 0\\.008637332530307587\ \(0\)\
\-\ hemangioma\\:\\ 0\\.008580463258881761\ \(0\)\
\-\ \\,\\:\\ 0\\.008516721162341626\ \(0\)\
\-\ pathologic\\:\\ 0\\.008405268783668925\ \(0\)\
\-\ young\\:\\ 0\\.008363524096988172\ \(0\)\
\-\ growth\\:\\ 0\\.00834977976661191\ \(0\)\
\-\ count\\:\\ 0\\.00834977976661191\ \(0\)\
\-\ have\\:\\ 0\\.008316575633101536\ \(0\)\
\-\ room\\:\\ 0\\.008255853634750199\ \(0\)\
\-\ mildly\\:\\ 0\\.008178356609871167\ \(0\)\
\-\ inflammation\\:\\ 0\\.00816569634533576\ \(0\)\
\-\ addition\\:\\ 0\\.008140587804665816\ \(0\)\
\-\ limited\\:\\ 0\\.008103443305899051\ \(0\)\
\-\ general\\:\\ 0\\.00809119700305059\ \(0\)\
\-\ caused\\:\\ 0\\.008054853499127893\ \(0\)\
\-\ amount\\:\\ 0\\.008019088431024748\ \(0\)\
\-\ rule\\:\\ 0\\.008019088431024748\ \(0\)\
\-\ occurs\\:\\ 0\\.0078814623068883\ \(0\)\
\-\ treatment\\:\\ 0\\.0077735593689927515\ \(0\)\
\-\ patient\\:\\ 0\\.00769970274981023\ \(0\)\
\-\ irregular\\:\\ 0\\.007659205960688494\ \(0\)\
\-\ rare\\:\\ 0\\.007456966738591677\ \(0\)\
\-\ based\\:\\ 0\\.0073228996904875525\ \(0\)\
\-\ 50\\:\\ 0\\.007305613520547876\ \(0\)\
\-\ emergency\\:\\ 0\\.00727143505164107\ \(0\)\
\-\ course\\:\\ 0\\.007246138075181217\ \(0\)\
\-\ has\\:\\ 0\\.007212134698850688\ \(0\)\
\-\ which\\:\\ 0\\.007169189156146287\ \(0\)\
\-\ calcifications\\:\\ 0\\.0071396938306354\ \(0\)\
\-\ laboratory\\:\\ 0\\.007076610642368688\ \(0\)\
\-\ involvement\\:\\ 0\\.007038064396916442\ \(0\)\
\-\ dilated\\:\\ 0\\.006977733497958717\ \(0\)\
\-\ pelvis\\:\\ 0\\.006977733497958717\ \(0\)\
\-\ did\\:\\ 0\\.006933525035939156\ \(0\)\
\-\ muscle\\:\\ 0\\.00689733760320527\ \(0\)\
\-\ typically\\:\\ 0\\.00677848487529432\ \(0\)\
\-\ obstruction\\:\\ 0\\.00677168550244817\ \(0\)\
\-\ or\\:\\ 0\\.006751838757058703\ \(0\)\
\-\ being\\:\\ 0\\.006691658374832716\ \(0\)\
\-\ presentation\\:\\ 0\\.006614383448294568\ \(0\)\
\-\ given\\:\\ 0\\.006582953691047961\ \(0\)\
\-\ elevated\\:\\ 0\\.006515317665975423\ \(0\)\
\-\ thickening\\:\\ 0\\.006509268695940117\ \(0\)\
\-\ on\\:\\ 0\\.006506885504408343\ \(0\)\
\-\ less\\:\\ 0\\.006503235964770073\ \(0\)\
\-\ left\\:\\ 0\\.006445653500716279\ \(0\)\
\-\ cases\\:\\ 0\\.006397327784227264\ \(0\)\
\-\ by\\:\\ 0\\.006394925407842134\ \(0\)\
\-\ \\>\\:\\ 0\\.0063801517183563255\ \(0\)\
\-\ white\\:\\ 0\\.0063687735117124\ \(0\)\
\-\ along\\:\\ 0\\.006346188487322509\ \(0\)\
\-\ out\\:\\ 0\\.006346188487322509\ \(0\)\
\-\ study\\:\\ 0\\.0063182727120448525\ \(0\)\
\-\ cancer\\:\\ 0\\.006312730931156777\ \(0\)\
\-\ radiation\\:\\ 0\\.006301688201263678\ \(0\)\
\-\ further\\:\\ 0\\.006106616048989345\ \(0\)\
\-\ follow\\:\\ 0\\.0061015718470706385\ \(0\)\
\-\ will\\:\\ 0\\.006007822513211555\ \(0\)\
\-\ such\\:\\ 0\\.00600299503335023\ \(0\)\
\-\ approximately\\:\\ 0\\.005941163655181086\ \(0\)\
\-\ age\\:\\ 0\\.005844742304593947\ \(0\)\
\-\ fat\\:\\ 0\\.005840252410969963\ \(0\)\
\-\ renal\\:\\ 0\\.005769607976310268\ \(0\)\
\-\ treated\\:\\ 0\\.005747979406930021\ \(0\)\
\-\ negative\\:\\ 0\\.0057351014862356735\ \(0\)\
\-\ 6\\:\\ 0\\.0057351014862356735\ \(0\)\
\-\ from\\:\\ 0\\.005691845901816685\ \(0\)\
\-\ abdomen\\:\\ 0\\.005688503961563363\ \(0\)\
\-\ in\\:\\ 0\\.00568176040638546\ \(0\)\
\-\ years\\:\\ 0\\.005638748622513444\ \(0\)\
\-\ demonstrated\\:\\ 0\\.005634651645970714\ \(0\)\
\-\ evaluation\\:\\ 0\\.005578064709723164\ \(0\)\
\-\ not\\:\\ 0\\.005549746839289597\ \(0\)\
\-\ appearance\\:\\ 0\\.0054919248915385206\ \(0\)\
\-\ through\\:\\ 0\\.005453835996451391\ \(0\)\
\-\ include\\:\\ 0\\.005386861770854577\ \(0\)\
\-\ ct\\:\\ 0\\.005372151251200193\ \(0\)\
\-\ secondary\\:\\ 0\\.005368606666311927\ \(0\)\
\-\ he\\:\\ 0\\.005357724364119146\ \(0\)\
\-\ performed\\:\\ 0\\.005354108609499594\ \(0\)\
\-\ an\\:\\ 0\\.005310853322628\ \(0\)\
\-\ history\\:\\ 0\\.005304335000930712\ \(0\)\
\-\ presented\\:\\ 0\\.005234511539376201\ \(0\)\
\-\ up\\:\\ 0\\.005163701463043199\ \(0\)\
\-\ cyst\\:\\ 0\\.005160384575339557\ \(0\)\
\-\ enhancement\\:\\ 0\\.005147165766568621\ \(0\)\
\-\ mild\\:\\ 0\\.005056749334676713\ \(0\)\
\-\ patients\\:\\ 0\\.004969830560373092\ \(0\)\
\-\ over\\:\\ 0\\.004889084472224635\ \(0\)\
\-\ abdominal\\:\\ 0\\.004799818512633967\ \(0\)\
\-\ acute\\:\\ 0\\.0047413018631606635\ \(0\)\
\-\ consistent\\:\\ 0\\.004708535435575738\ \(0\)\
\-\ pain\\:\\ 0\\.004690373786654988\ \(0\)\
\-\ soft\\:\\ 0\\.004676239919086629\ \(0\)\
\-\ surgery\\:\\ 0\\.004662919245753427\ \(0\)\
\-\ bilateral\\:\\ 0\\.004660264560257178\ \(0\)\
\-\ 1\\:\\ 0\\.004569272736988106\ \(0\)\
\-\ tissue\\:\\ 0\\.004551508288657515\ \(0\)\
\-\ imaging\\:\\ 0\\.0044990423021474225\ \(0\)\
\-\ \\%\\:\\ 0\\.004479373108642714\ \(0\)\
\-\ other\\:\\ 0\\.004426154042027975\ \(0\)\
\-\ demonstrate\\:\\ 0\\.004418993576029305\ \(0\)\
\-\ were\\:\\ 0\\.004360194015033531\ \(0\)\
\-\ can\\:\\ 0\\.0043555558482451006\ \(0\)\
\-\ case\\:\\ 0\\.004201133557005103\ \(0\)\
\-\ large\\:\\ 0\\.004198971756923775\ \(0\)\
\-\ demonstrates\\:\\ 0\\.004194654385737497\ \(0\)\
\-\ findings\\:\\ 0\\.004087274013011145\ \(0\)\
\-\ female\\:\\ 0\\.0039477758908940085\ \(0\)\
\-\ of\\:\\ 0\\.003927094408920959\ \(0\)\
\-\ no\\:\\ 0\\.003867164722264279\ \(0\)\
\-\ within\\:\\ 0\\.0036632166480586106\ \(0\)\
\-\ that\\:\\ 0\\.0033168106259748842\ \(0\)\
\-\ for\\:\\ 0\\.003276890555697596\ \(0\)\
\-\ and\\:\\ 0\\.0032361169569837026\ \(0\)\
\-\ as\\:\\ 0\\.002904668552571074\ \(0\)\
\-\ there\\:\\ 0\\.0028577877673370534\ \(0\)\
\-\ are\\:\\ 0\\.002617694095572139\ \(0\)\
\-\ \\.\\:\\ 0\\.0024730013910510885\ \(0\)\
\-\ old\\:\\ 0\\.001966145161488213\ \(0\)\
\-\ with\\:\\ 0\\.0015775843967176144\ \(0\)\
